Celebrating Cresemba's Success in the Japanese Market
Basilea Pharmaceutica Ltd has recently hit a significant milestone with the launch of their antifungal drug, Cresemba, in Japan. This success was highlighted when the sales of Cresemba exceeded a key threshold, triggering a milestone payment from its partner, Asahi Kasei Pharma (AKP), valued at approximately CHF 1.2 million. This remarkable achievement underscores the potential of Cresemba in a market that holds considerable promise for growth.
The Significance of Sales Milestones
For Basilea, reaching this sales milestone so early in the commercialization phase is a notable accomplishment. David Veitch, the Chief Executive Officer of Basilea, expressed his excitement regarding Japan's status as a vital market. He believes that the swift escalation in sales indicates the effectiveness of their partner AKP in addressing the urgent medical needs posed by severe fungal infections within the Japanese healthcare system.
Understanding Cresemba
Cresemba, known generically as isavuconazole, is available in both intravenous and oral formulations. It has been specifically approved in Japan for treating adult patients suffering from severe fungal conditions such as aspergillosis, mucormycosis, and cryptococcosis. These conditions can be life-threatening, making effective antifungal medications critical for patient care.
Global Reach and Impact of Cresemba
By the end of the previous year, Cresemba was available in more than 70 countries worldwide. Recent market data paints an impressive picture, with total global sales reaching USD 533 million between certain time periods, reflecting a year-on-year growth of 20 percent. This rapid growth solidifies Cresemba's position as the leading antifungal treatment for invasive fungal infections globally.
Basilea: Committed to Innovation
Basilea Pharmaceutica, founded in 2000 and headquartered in Switzerland, is dedicated to developing innovative therapies aimed at combating severe bacterial and fungal infections. With a growing portfolio that includes two major brands, Cresemba and Zevtera, Basilea is focused on addressing critical health needs. Their commitment to research and development ensures that they remain at the forefront of biopharmaceutical advancements.
Contact Information for Inquiries
If you would like more information about Basilea or their products, you can reach out to Peer Nils Schröder, PhD, Head of Corporate Communications and Investor Relations, via phone at +41 61 606 1102 or through email at media_relations@basilea.com or investor_relations@basilea.com.
Frequently Asked Questions
1. What is Cresemba and its primary use?
Cresemba (isavuconazole) is an antifungal medication used for treating serious fungal infections such as aspergillosis and cryptococcosis.
2. When was Cresemba launched in Japan?
Cresemba was launched in Japan recently and has already exceeded sales thresholds that triggered a milestone payment.
3. How much was the milestone payment from AKP to Basilea?
The milestone payment received from Asahi Kasei Pharma amounted to approximately CHF 1.2 million.
4. In how many countries is Cresemba currently available?
Cresemba is available in more than 70 countries around the world.
5. Who can be contacted for more information about Basilea?
For inquiries regarding Basilea, contact Peer Nils Schröder at +41 61 606 1102 or via email.
